Treats urinary tract infections. ANDA 74967, held by Aurobindo Pharma USA. Nitrofurantoin, Macrocrystalline.
As of Nov 16, 2026, ANDA 74967 (Nitrofurantoin), held by Aurobindo Pharma USA, was first approved by FDA on Jul 9, 1997, with 9 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE: Nitrofurantoin capsules (macrocrystals) are specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci, Staphylococcus aureus, and certain susceptible strains of Klebsiella and Enterobacter species. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 9, 1997 | Original application | Approved |
| Nitrofurantoin50MG · capsule;oral | Nitrofurantoin, Macrocrystalline | Rx |
| Nitrofurantoin100MG · capsule;oral | Nitrofurantoin, Macrocrystalline | Rx |
| Dec 11, 2023 | Supplement 15Labeling · Standard review | Approved | None posted |
| Jan 15, 2015 | Supplement 12Labeling · Standard review | Approved | None posted |
| Nov 14, 2012 | Supplement 11Labeling · Standard review | Approved | None posted |
| Sep 18, 2012 | Supplement 10Labeling · Standard review | Approved | None posted |
| Nov 2, 2011 | Supplement 9Manufacturing | Approved | None posted |
| Sep 25, 2003 | Supplement 4Labeling | Approved | None posted |
| Apr 28, 2003 | Supplement 3Labeling | Approved | None posted |
| Aug 3, 1998 | Supplement 2Labeling | Approved | None posted |
| Jan 27, 1998 | Supplement 1Manufacturing | Approved | None posted |
| Jul 9, 1997 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters